Geron (NASDAQ:GERN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Geron (NASDAQ:GERN) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01), Zacks reports. The business had revenue of $57.48 million for the quarter, compared to analyst estimates of $55.30 million. Geron had a negative return on equity of 23.31% and a negative net margin of 35.48%.

Here are the key takeaways from Geron’s conference call:

• RYTELO net revenue rose 17% year over year to $57.5 million in the second quarter, while first-half revenue increased approximately 24% year over year.
• RYTELO demand grew 5% sequentially, prescribing accounts increased 8% to approximately 1,575, and the company expects 2026 net product revenue of $220 million-$240 million to land at the mid-to-high end of guidance.
• Management cited encouraging real-world evidence in lower-risk MDS that was generally consistent with the Phase III IMerge trial, supporting RYTELO adoption—particularly in earlier lines of therapy and community treatment centers.
• Geron ended the quarter with $327 million in cash, equivalents, restricted cash, and marketable securities, while maintaining 2026 operating expense guidance of $230 million-$240 million and reporting a 4% first-half decrease in operating expenses.
• The company is evaluating a modification to the interim event threshold for the Phase III IMpactMF myelofibrosis trial after discussions with regulators; although timelines remain unchanged, the base case still calls for final overall-survival analysis in the second half of 2028.

Geron Stock Performance

NASDAQ:GERN traded up $0.29 during mid-day trading on Wednesday, hitting $1.63. 36,057,531 shares of the stock were exchanged, compared to its average volume of 9,380,397. The firm’s 50-day simple moving average is $1.33 and its 200 day simple moving average is $1.46. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -14.82 and a beta of 0.61. Geron has a fifty-two week low of $1.04 and a fifty-two week high of $2.01. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.96 and a current ratio of 6.78.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Geron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Geron by 2.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after buying an additional 8,123 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Geron by 8.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,372,016 shares of the biopharmaceutical company’s stock valued at $2,182,000 after acquiring an additional 104,840 shares during the period. Legal & General Group Plc grew its stake in shares of Geron by 8.3% in the second quarter. Legal & General Group Plc now owns 550,871 shares of the biopharmaceutical company’s stock valued at $775,000 after acquiring an additional 42,345 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Geron by 4.1% in the second quarter. Rhumbline Advisers now owns 873,893 shares of the biopharmaceutical company’s stock valued at $1,232,000 after acquiring an additional 34,437 shares in the last quarter. Finally, Prudential Financial Inc. increased its position in Geron by 72.3% during the second quarter. Prudential Financial Inc. now owns 79,494 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 33,352 shares during the period. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.